Gilead Stock: 5 Reasons To Buy GILD Stock

- September 17, 2016
Image: TheCountryCaller

Image: TheCountryCaller

I’ve made some pretty bold calls about Gilead Sciences (NASDAQ:GILD) over the last few weeks. I said that Gilead stock would rise behind a huge acquisition, either Gilead acquired itself, or acquiring Acadia Pharmaceuticals (NASDAQ:ACAD). Both are very likely scenarios, and are at the epicenter of what makes GILD stock so great to own.

However, it is not just M&A that makes Gilead stock so appealing. There are bigger factors at play that often get overlooked. Based on the Gilead stock price, these factors are in fact forgotten.

5 reasons to buy Gilead stock

First, the valuation. Gilead’s HCV franchise may be losing year-over-year revenue, but it still has many years left with $10, even $15 billion in annual sales. In fact, based on its current products, Gilead will continue to earn around $15 billion in net profit for each of the next three years. Hence, GILD stock price supports a multiple of just 7x net profit. Most biotech and big pharma trade at multiples of more than 100% to Gilead.

Second, Gilead has more than Harvoni and Sovaldi. Both HCV drugs have been blessings, but Harvoni’s 29% decline and Sovaldi’s 5% rise in revenue has weighed heavily on GILD stock price. Collectively, the two drugs were responsible for 50% of total product sales. However, the other 50% is growing. Truvada is a blockbuster in its own right with last quarter sales of $942 million. It grew 11%. The fact that Harvoni and Sovaldi sales are starting to decline is fully considered in the valuation of Gilead. Although, GILD stock acts as though there is nothing more.

Third, Gilead has a surprisingly solid pipeline. The knock on GILD has always been it needs to acquire for growth. However, Epclusa is a new hep C oral drug that is the first to treat genotypes 2 and 3. Analysts believe it could do over $10 billion! Genvoya is a new HIV drug that was approved last November, and created over $400 million in the first six months of this year.

Beyond that Gilead has seven phase 3 clinical trials and 18 mid-stage studies in progress. Simtuzumab is Gilead’s NASH drug that should be FDA approved sometime in 2018. It has peak sales potential of $12 billion! Also in Phase 3 development is filgotinib, a rheumatoid arthritis drug that could reach $4 billion in peak sales. That said, everyone keeps waiting for Gilead to acquire its next big drug. However, it appears that Gilead already has several, in development.

Fourth, cash, cash equivalents, and short- and long-term marketable securities totals $24.6 billion. If you remove that cash from Gilead valuation, then GILD stock trades at just over 5x earnings.

Fifth, Gilead is putting cash to work. Gilead stock has a 2.4% dividend yield and the company bought back $9 billion in GILD stock the first half of 2016.

Collectively, this all matters when looking ahead. While Gilead stock may be down now, rest assure that these five factors will eventually pay off, and push GILD stock higher regardless of what it acquires or if it is acquired.

GILD stock: What makes me so confident

The rest of this content is exclusive to BNL Members only. (Unlock All Content & Much More)
  • Access all research reports, unlock hidden content, & follow stock coverage on more than 60 companies,
  • Know what stocks are being bought, sold, and held in the market beating BNL Portfolio, David's Dividend Portfolio, and Eddy's Options.
  • Get email notifications and mobile alerts the minute a trade is made. 
  • Join the fastest growing community of investors in the market, and engage with 100s of BNL Members in our Members Only section.

Learn More about BNL Membership and its no risk, no contract, guaranteed results policy!

Get our All Access Package for $85/month!

 

This entry was posted in Healthcare & Biotech, Mergers & Acquisitions Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

One Trackback

  1. […] far more developed and ready to become a short-term catalyst that most GILD stock owners realize, explained here. When you start to look at all the moving parts, it is clear that Gilead stock is a terrific […]

Post a Comment

You must be logged in to post a comment.







Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.


Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!

%d bloggers like this: